Case Report: Exploring delayed hyperprogressive disease: a case study of post-immunotherapy in lung cancer
This report is the first to present HPD after 5 months of immunotherapy, marking the longest recorded occurrence of this phenomenon. This particular case of post-immunotherapy HPD achieved satisfactory results through targeted segment arterial chemoembolization, offering a potential approach for managing this side effect.
Authors
- Qiu-Lian Liu
- Kexin Cao (ORCID: https://orcid.org/0000-0002-1846-508X)
- Jie Zhou (ORCID: https://orcid.org/0000-0001-5078-3136)
- Guoping Ai (ORCID: https://orcid.org/0000-0003-4905-9129)
- Biao Wang (ORCID: https://orcid.org/0000-0003-1557-5045)
- Mengjie Li (ORCID: https://orcid.org/0000-0002-0619-8754)
- Jian Zhu (ORCID: https://orcid.org/0000-0002-1768-5312)
- Jinxia Wei
Institutions
- Jiujiang First People's Hospital (CN)
- First Affiliated Hospital of Xinxiang Medical University (CN)
- Central Hospital of Wuhan (CN)
- Wuhan General Hospital of Guangzhou (CN)
- General Hospital of Central Theater Command
- Henan Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-17
- DOI
- https://doi.org/10.3389/fimmu.2025.1552547
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese People’s Liberation Army